This company has been marked as potentially delisted and may not be actively trading. Revance Therapeutics (RVNC) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock Get the Latest News and Ratings for RVNC and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Revance Therapeutics and its competitors. Enter your email to sign up for newsletter Sign Up RVNC Analyst Ratings Over TimeTypeCurrent Forecast7/12/24 to 7/12/251 Month Ago6/12/24 to 6/12/253 Months Ago4/13/24 to 4/13/251 Year Ago7/13/23 to 7/12/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)4 Buy rating(s)Hold7 Hold rating(s)7 Hold rating(s)8 Hold rating(s)4 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$8.45$8.45$8.39$11.50Forecasted Upside131.51% Upside131.51% Upside129.75% Upside221.23% UpsideConsensus RatingHoldHoldHoldModerate Buy RVNC Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History RVNC Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Revance Therapeutics Stock vs. The CompetitionTypeRevance TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 2.13 2.80 2.54Consensus RatingHoldModerate BuyModerate BuyPredicted Upside131.51% Upside8,634.01% Upside10.52% UpsideNews Sentiment RatingNeutral NewsSee Recent RVNC NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails1/17/2025Needham & Company LLC2 of 5 starsS. BelangerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold12/23/2024Barclays3 of 5 starsB. PrasadSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower TargetEqual Weight ➝ Equal Weight$7.00 ➝ $3.00-2.91%12/10/2024Mizuho3 of 5 stars Lower TargetNeutral ➝ Neutral$6.66 ➝ $3.10+2.31%11/8/2024HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingD. TsaoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$6.60 ➝ $6.60+76.94%8/12/2024Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingD. AmsellemSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/12/2024GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingS. FernandezSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral8/12/2024William BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingT. LugoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform8/9/2024Stifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy ➝ Buy$24.00 ➝ $20.00+577.96%5/13/2024The Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetNeutral ➝ Neutral$9.00 ➝ $8.00+146.91%10/11/2023Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetEqual Weight ➝ Equal Weight$25.00 ➝ $12.00+21.83% Get the Latest News and Ratings for RVNC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/16/2023BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeUnderperform ➝ Neutral$20.00+6.38%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:11 PM ET. RVNC Forecast - Frequently Asked Questions What is Revance Therapeutics' forecast for 2025? According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Revance Therapeutics is $8.45, with a high forecast of $20.00 and a low forecast of $3.00. Should I buy or sell Revance Therapeutics stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" RVNC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RVNC, but not buy additional shares or sell existing shares. Does Revance Therapeutics's stock price have much upside? According to analysts, Revance Therapeutics's stock has a predicted upside of 131.51% based on their 12-month stock forecasts. Do Wall Street analysts like Revance Therapeutics more than its competitors? Analysts like Revance Therapeutics less than other "medical" companies. The consensus rating for Revance Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RVNC compares to other companies. Stock Forecasts and Research Tools Related Companies Biohaven Stock Forecast Evotec Stock Forecast 89BIO Stock Forecast Janux Therapeutics Stock Forecast ANI Pharmaceuticals Stock Forecast Edgewise Therapeutics Stock Forecast Mesoblast Stock Forecast Travere Therapeutics Stock Forecast CureVac Stock Forecast Structure Therapeutics Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:RVNC) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredDid you miss out on Trump’s “birthday gift” to Americans?While protestors were rallying against “King Trump,” one trader quietly spotted a 15% weekend move tied to his...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revance Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
